Network pharmacology and bioinformatics analysis on the underlying mechanisms of baicalein against oral squamous cell carcinoma

被引:9
|
作者
Tang, Bohan [1 ]
Dong, Yue [2 ]
机构
[1] Dalian Med Univ, Sch Stomatol, Dalian, Peoples R China
[2] Osaka Univ, Grad Sch Med, Osaka, Japan
关键词
baicalein; drug discovery; natural products; network pharmacology; oral squamous cell carcinoma; HYPOXIA-INDUCIBLE FACTORS; WEB SERVER; CANCER; APOPTOSIS; ACTIVATION; SURVIVAL; INVASION; CD4(+); GENES; HEAD;
D O I
10.1002/jgm.3490
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background and aimsThis study performed a network pharmacology analysis to explore the potential anticancer activity of baicalein against oral squamous cell carcinoma (OSCC). MethodsThe differentially expressed genes in OSCC were identified by the OSCC, and the key module related to OSCC was acquired by the weighted gene co-expression network analysis from GSE30784. Baicalein targets were obtained from GeneCards, SwissTargetPrediction and TCMSP (the traditional Chinese medicine systems pharmacology database and analysis platform) databases. Apart from GSE30784, OSCC-related genes were acquired from the Comparative Toxicogenomics Database and DisGeNET platform. The baicalein targets and OSCC-related genes were overlapped to acquire the drug-disease interaction genes. We input the candidate drug-disease interaction genes into the STRING database and created the protein-protein interaction network. The hub genes in the network were identified by cytoHubba. The expression levels of hub genes between cancer tissues and normal tissues were evaluated based on The Cancer Genome Atlas. Moreover, we performed the cancer immune infiltration analysis and evaluated the association between the expression of HIF1A and the abundance of infiltrating immune cells. The molecular docking between HIFA and baicalein was also performed and visualized. Additionally, the enrichment analysis was performed based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes database. ResultsAfter overlapping the candidate baicalein targets with OSCC-related genes, 34 candidate drug-disease interaction genes were obtained. cytoHubba identified the top 10 genes with high centrality measures from the network, including AKT1, CD44, EGFR, HIF1A, IGF1, MMP2, MYC, PTGS2, STAT3 and TP53. The enriched biological process terms included regulation of apoptotic signaling pathway, regulation of cysteine-type endopeptidase activity and cellular response to chemical stress. The top five enriched pathways comprised Kaposi sarcoma-associated herpesvirus infection, hepatitis C, p53 signaling pathway, Epstein-Barr virus infection and proteoglycans in cancer. The expression of HIF1A was positively associated with the infiltration levels of CD4 + T cells (cor = 0.131, p = 0.004) and dendritic cells (cor = 0.098, p = 0.03), whereas negatively associated with B cells (cor = -0.098, p = 0.03). ConclusionOur results suggested that baicalein might be a candidate drug against OSCC. More studies are necessary to validate its anticancer effect and explore the underlying mechanisms.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] NK cell based immunotherapy against oral squamous cell carcinoma
    Zhang, Ying
    Xie, Jianming
    Wu, Haoran
    Huang, Jinhui
    Zheng, Danna
    Wang, Shaotong
    Jia, Xueqiang
    He, Zongzhong
    Gong, Ying
    Ju, Linling
    Sun, Qiurong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [32] Bioinformatics Analysis Reveals Significant Genes and Pathways to Targetfor Oral Squamous Cell Carcinoma
    Jiang, Qian
    Yu, You-Cheng
    Ding, Xiao-Jun
    Luo, Yin
    Ruan, Hong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 2273 - 2278
  • [33] Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis
    Wei, Junwei
    Ma, Luyuan
    Liu, Wenpeng
    Wang, Yadong
    Shen, Chuan
    Zhao, Xin
    Zhao, Caiyan
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 276
  • [34] Identification of molecular targets and underlying mechanisms of Fuzheng Shengbai Decoction against colon cancer based on network pharmacology
    Wang, Yu
    Wang, Shuiming
    Li, Min
    Zhang, Qijia
    Fang, Mingzhi
    Zheng, Qin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (09): : 4320 - 4342
  • [35] Network Pharmacology and Bioinformatics Analysis to Identify the Molecular Targets and its Biological Mechanisms of Sciadopitysin against Glioblastoma
    Lian, Haiwei
    Xiong, Yajie
    Zhao, Guojie
    Yi, Meng
    Wang, Jingchao
    Liu, Huimin
    Zhou, Yun
    JOURNAL OF CANCER, 2024, 15 (12): : 3675 - 3683
  • [36] Tumour budding in oral squamous cell carcinoma: a meta-analysis
    Almangush, Alhadi
    Pirinen, Matti
    Heikkinen, Ilkka
    Makitie, Antti A.
    Salo, Tuula
    Leivo, Ilmo
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 577 - 586
  • [37] Survival Analysis of Oral Squamous Cell Carcinoma in a Subgroup of Young Patients
    Fan, Yi
    Zheng, Lei
    Mao, Ming-Hui
    Huang, Ming-Wei
    Liu, Shu-Ming
    Zhang, Jie
    Li, Sheng-Lin
    Zheng, Lei
    Zhang, Jian-Guo
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8887 - 8891
  • [38] Molecular Mechanisms of Inhibitory Effects of Bovine Lactoferrin on Invasion of Oral Squamous Cell Carcinoma
    Chea, Chanbora
    Miyauchi, Mutsumi
    Inubushi, Toshihiro
    Okamoto, Kana
    Haing, Sivmeng
    Takata, Takashi
    PHARMACEUTICS, 2023, 15 (02)
  • [39] Evaluation of MAGE A1 in oral squamous cell carcinoma
    Pereira, Claudia Maria
    Gomes, Carolina Cavalieri
    Correia Silva, Jeane De Fatima
    Rodriguez, Monica Bucciarelli
    Barbosa, Alvimar Afonso
    Gomez, Ricardo Santiago
    ONCOLOGY REPORTS, 2012, 27 (06) : 1843 - 1848
  • [40] Exploring the Mechanism of Scutellaria baicalensis Georgi Efficacy against Oral Squamous Cell Carcinoma Based on Network Pharmacology and Molecular Docking Analysis
    Hou, Fanfan
    Liu, Yang
    Cheng, YaHsin
    Zhang, Ni
    Yan, Wenpeng
    Zhang, Fang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021